Drug intelligence / Profile preview

AAV.PHPeB

Development stage
Preclinical
Lead developer
Regel Therapeutics
Modality
Gene Therapies
Administration
Intravenous
01

Overview

AAV.PHPeB is an engineered adeno-associated virus (AAV) capsid platform derived from AAV9, specifically optimized for high-efficiency crossing of the blood-brain barrier (BBB) and widespread neuronal transduction following systemic (intravenous) administration. Developed at the California Institute of Technology, it is widely used in preclinical research to deliver gene modulation tools to the central nervous system. In the development of therapies for SCN2A haploinsufficiency, such as those by Regel Therapeutics, AAV.PHPeB has been utilized to screen and characterize neuron-specific regulatory elements (REs) and to deliver payloads like dCas9-VP64. These payloads are designed to upregulate the SCN2A gene, thereby restoring functional levels of the Nav1.2 sodium channel protein to treat associated neurodevelopmental disorders, including autism and epilepsy.

Other names
AAV-PHP.eB
02

Targets

Ly6A (Lymphocyte antigen 6 complex locus A)AAVR (AAV receptor)

Beyond the preview

Go deeper on AAV.PHPeB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAV.PHPeB.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call